Webinar - The End of Statistical Significance Testing

March 28, 2019

The End of Statistical Significance Testing

Meet Our Team

Kenneth J. Rothman, DrPH Distinguished Fellow, Vice President of Epidemiology Research

Heather Danysh, PhD Research Epidemiologist

2

Physician's Health Study

Acute MI Stroke Ischemic Heart Disease Sudden Death Other Cardiovascular Other Cerebrovascular

Aspirin N= 11,037

5 6

9

13

10

1

Placebo N=11,034 RR 95% CI

18

0.25 0.11--0.56

2

3.00 0.75--12.0

8

1.08 0.42--2.8

9

1.49 0.65--3.4

6

1.79 0.67--4.76

1

1.00 0.06--16.0

"Furthermore, among the six categories of deaths from vascular causes, there was no significant excess in the aspirin group within any single category that would counterbalance the deficit in fatal myocardial infarction (5 in the aspirin group and 18 in the placebo group)."

NEJM 1988; 318:262-264

3

Physician's Health Study

Acute MI Stroke Ischemic Heart Disease Sudden Death Other Cardiovascular Other Cerebrovascular Total Cardiovascular

Aspirin N= 11,037

5 6

9 13 10 1 44

Placebo N=11,034 RR 95% CI

18

0.25 0.11--0.56

2

3.00 0.75--12.0

8

1.08 0.42--2.8

9

1.49 0.65--3.4

6

1.79 0.67--4.76

1

1.00 0.06--16.0

44

0.99 0.65--1.5

"Furthermore, among the six categories of deaths from vascular causes, there was no significant excess in the aspirin group within any single category that would counterbalance the deficit in fatal myocardial infarction (5 in the aspirin group and 18 in the placebo group)."

NEJM 1988; 318:262-264

4

Physician's Health Study

Acute MI Stroke Ischemic Heart Disease Sudden Death Other Cardiovascular Other Cerebrovascular Total Cardiovascular

Aspirin N= 11,037

5 6

9 13 10 1 44

Placebo N=11,034

18 2

8 9 6 1 44

RR 95% CI

0.25 0.11--0.56 3.00 0.75--12.0 1.08 0.42--2.8 1.49 0.65--3.4 1.79 0.67--4.76 1.00 0.06--16.0 0.99 0.65--1.5

P-value 0.006 0.16 0.81 0.40 0.31 1.00 0.99

"Furthermore, among the six categories of deaths from vascular causes, there was no significant excess in the aspirin group within any single category that would counterbalance the deficit in fatal myocardial infarction (5 in the aspirin group and 18 in the placebo group)."

NEJM 1988; 318:262-264

5

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download